Understanding the Impact of IBS in Australia The Implications of Anatara Lifesciences GaRP-IBS Trial - The Australian Business Journal
| ANR Stock | 0.05 0 8.00% |
Slightly above 61% of Anatara Lifesciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Anatara Lifesciences suggests that many traders are alarmed. Anatara Lifesciences' investing sentiment can be driven by a variety of factors including economic data, Anatara Lifesciences' earnings reports, geopolitical events, and overall market trends.
Anatara |
Understanding the Impact of IBS in Australia The Implications of Anatara Lifesciences GaRP-IBS Trial The Australian Business Journal
Read at news.google.com
 |
Anatara Lifesciences Fundamental Analysis
We analyze Anatara Lifesciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anatara Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anatara Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Anatara Lifesciences is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Anatara Lifesciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Anatara Lifesciences stock to make a market-neutral strategy. Peer analysis of Anatara Lifesciences could also be used in its relative valuation, which is a method of valuing Anatara Lifesciences by comparing valuation metrics with similar companies.
Peers
Anatara Lifesciences Related Equities
| AVC | Auctus Alternative | 14.58 | ||||
| CIW | Clime Investment | 3.03 | ||||
| FSI | Flagship Investments | 0.46 | ||||
| BKI | BKI Investment | 0.58 | ||||
| AUI | Australian United | 0.65 | ||||
| SNC | Sandon Capital | 1.30 | ||||
| MAQ | Macquarie Technology | 3.38 |
Additional Tools for Anatara Stock Analysis
When running Anatara Lifesciences' price analysis, check to measure Anatara Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anatara Lifesciences is operating at the current time. Most of Anatara Lifesciences' value examination focuses on studying past and present price action to predict the probability of Anatara Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anatara Lifesciences' price. Additionally, you may evaluate how the addition of Anatara Lifesciences to your portfolios can decrease your overall portfolio volatility.